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   ABSTRACT   
  Background      Patients with systemic lupus 
erythematosus (SLE) are at increased risk of 
atherosclerosis, even after accounting for traditional 
risk factors. High levels of leptin and low levels of 
adiponectin are associated with both atherosclerosis and 
immunomodulatory functions in the general population.   
  Objective      To examine the association between these 
adipokines and subclinical atherosclerosis in SLE, and 
also with other known inﬂ  ammatory biomarkers of 
atherosclerosis.  
  Methods      Carotid ultrasonography was performed in 
250 women with SLE and 122 controls. Plasma leptin and 
adiponectin levels were measured. Lipoprotein a (Lp(a)), 
oxidised phospholipids on apoB100 (OxPL/apoB100), 
paraoxonase, apoA-1 and inﬂ  ammatory high-density 
lipoprotein (HDL) function were also assessed.   
  Results      Leptin levels were signiﬁ  cantly higher in 
patients with SLE than in controls (23.7±28.0 vs 
13.3±12.9 ng/ml, p<0.001). Leptin was also higher 
in the 43 patients with SLE with plaque than without 
plaque (36.4±32.3 vs 20.9±26.4 ng/ml, p=0.002). 
After multivariate analysis, the only signiﬁ  cant factors 
associated with plaque in SLE were leptin levels in the 
highest quartile (≥29.5 ng/ml) (OR=2.8, p=0.03), 
proinﬂ  ammatory HDL (piHDL) (OR=12.8, p<0.001), age 
(OR=1.1, p<0.001), tobacco use (OR=7.7, p=0.03) 
and hypertension (OR=3.0, p=0.01). Adiponectin levels 
were not signiﬁ  cantly associated with plaque in our 
cohort. A signiﬁ  cant correlation between leptin and piHDL 
function (p<0.001), Lp(a) (p=0.01) and OxPL/apoB100 
(p=0.02) was also present.   
  Conclusions      High leptin levels greatly increase the 
risk of subclinical atherosclerosis in SLE, and are also 
associated with an increase in inﬂ  ammatory biomarkers 
of atherosclerosis such as piHDL, Lp(a) and OxPL/
apoB100. High leptin levels may help to identify patients 
with SLE at risk of atherosclerosis.           
  Young women with systemic lupus erythematosus 
(SLE) have up to a 50 times higher risk of cardio-
vascular events than age-matched controls,  1   even 
after consideration of traditional Framingham risk 
factors.  1    –    3   It has increasingly become evident that 
inﬂ   ammation and immune mechanisms play an 
important role in the pathogenesis of atheroscle-
rosis in SLE, and that new methods are needed 
to predict which patients with SLE are at risk of 
  cardiovascular morbidity. 
  The adipokine leptin functions as a hypotha-
lamic modulator of food intake, body weight and 
fat stores.  4   High circulating leptin levels are seen 
in overweight individuals,  5     6   suggesting that obese 
patients develop leptin resistance similar to insulin 
resistance in type II diabetes.  7   Hyperleptinaemia 
in the general population is also associated with 
atherosclerosis, hypertension and metabolic syn-
drome.  5     8   Conversely, adiponectin is the most 
abundant human plasma adipocytokine, and levels 
are reduced in type II diabetes and cardiovascu-
lar disease (CVD).  9   In addition to the established 
role of adipokines in energy homoeostasis, leptin 
and adiponectin also have immunomodulatory 
roles.  10   The dual roles of adipokines in the regula-
tion of metabolism and the immune system have 
led some investigators to postulate that adipokines 
may provide a link between immune responses and 
atherosclerosis.  10   
  Several previous small cohort studies have 
shown elevated leptin and adiponectin levels in 
adult  5     11     12   and paediatric  13   patients with SLE. 
This study was designed to determine if leptin and 
adiponectin levels predict subclinical atheroscle-
rosis in SLE. Furthermore, we sought to examine 
whether adipokine levels are associated with other 
inﬂ  ammatory biomarkers of atherosclerosis in SLE 
such as proinﬂ  ammatory high-density lipoprotein 
(piHDL), oxidised phospholipid (OxPL)/apoB100 
ratio and lipoprotein a (Lp(a)). 
  METHODS 
  Study  population 
  Two hundred and ﬁ   fty patients with SLE and 
122 controls from our longitudinal Biomarkers of 
Atherosclerosis in SLE Cohort Study were included, 
based on the availability of baseline plasma sam-
ples. No signiﬁ  cant demographic or clinical differ-
ences existed between subjects included here in 
comparison with the larger cohort. Study protocol 
details have been reported elsewhere.  14   In brief, 
participants were recruited prospectively from 
the rheumatology practices of the University of 
California Los Angeles (UCLA) and Cedars Sinai 
Medical Center in Los Angeles between February 
2004 and February 2008. Eligible participants were 
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women aged ≥18 years. Patients with SLE fulﬁ  lled at least four 
of the 1997 revised American College of Rheumatology (ACR) 
classiﬁ   cation criteria for SLE.  15   The controls were women, 
healthy by self-report, with no clinical manifestations of SLE 
on Connective Tissue Screening Questionnaire.  16   Because 
  statins  17   and renal failure  18   are known to alter HDL inﬂ  am-
matory function (one of the target biomarkers of the study), 
subjects were excluded if they had taken statins within the 
previous 3 months, or if they had renal failure (deﬁ  ned as cre-
atinine >2.0 mg/dl). Demographic data are shown in   table 1  . 
The study was approved by the institutional review boards at 
UCLA and Cedars-Sinai Medical Center; all participants gave 
written informed consent.     
  Sample  collection 
  All eligible consenting subjects provided a blood sample, under-
went a carotid ultrasound and completed a set of questionnaires. 
Plasma lipids and levels of high-sensitivity C-reactive protein 
were measured in the UCLA clinical laboratory by standard 
methods. On the day of plasma sampling, SLE disease activity 
was assessed using Safety of Estrogens in Lupus Erythematosus—
National Assessment/SLE Disease Activity Index.  19   Organ dam-
age was determined using the Systemic Lupus International 
Collaborating Clinics/ACR Damage Index (SDI).  20   Height and 
weight were measured, and body mass index (BMI) was calcu-
lated. Information about cardiac risk factors and current drugs 
were obtained from self-administered health history question-
naires and conﬁ  rmed by a study doctor using chart review.   
  Carotid  ultrasound 
  B (brightness)-mode grey scale, colour and spectral Doppler tech-
niques were used to investigate the carotid arteries according to 
a standardised protocol.  14   The same radiologist (NR) interpreted 
all studies in a blinded fashion, and the same ultrasound unit 
(Iu22; Philips Medical Systems, Bothell, Washington, USA) was 
used for scanning all participants. 
  The following anatomical sites were examined for the pres-
ence of atherosclerotic plaque, deﬁ  ned as the presence of focal 
protrusion into the arterial lumen with a thickness exceeding 
that of the surrounding wall by at least 50%: the bilateral com-
mon carotid, internal carotid, external carotid and vertebral 
arteries, and the carotid bulbs. The number, location and sono-
graphic appearance of the plaques were recorded. Intima-media 
thickness (IMT) of the far wall of the distal common carotid 
artery was measured (1) 1 cm proximal to the ﬂ  ow divider, (2) 
at end diastole and (3) using automated QLAB software (Philips 
Medical Systems). IMT was never measured at the level of a 
plaque and is presented as the average of three values of the left 
and right segments.   
  Measurement  of  inﬂ  ammatory lipids and adipokines 
  Plasma leptin (BioVendor, Candler, North Carolina, USA), adi-
ponectin (R&D Systems, Minneapolis, Minnesota, USA) and 
apoA-1 levels (Mabtech, Cincinnati, Ohio, USA) were measured 
using ELISA. HDL function was measured as described.  14   Values 
≥1.0 after the addition of test HDL-cholesterol indicated dysfunc-
tional, piHDL; values <1.0 indicated normal, anti-inﬂ  ammatory 
HDL. Plasma paraoxonase (PON1) activity was measured using 
paraoxon as a substrate as described.  21   Lp(a) was measured as 
described,  22   and levels of OxPL/apoB100 were detected with the 
monoclonal antibody E06  22   in a subset of 179 patients with SLE 
(the ﬁ  rst 179 subjects enrolled in the study). For each assay, the 
interassay and intra-assay variation was <8%.   
  Statistical  analysis 
  Data were analysed using SPSS 13.0 (SPSS, Chicago, Illinois, 
USA, 2005). Skewed continuous variables were logarithmi-
cally transformed to attain a normal distribution (note: non-
transformed data are presented in ﬁ  gures and tables to facilitate 
interpretation of results). For variables that did not attain a nor-
mal distribution by logarithmic transformation, non-parametric 
tests were used. Study groups were compared using analysis 
of variance/Student t test for continuous parametric variables, 
Mann–Whitney test for non-parametric variables and the χ  2   test 
for categorical variables. Either Pearson or Spearman rank cor-
relation was calculated, depending on whether or not the vari-
able was normally distributed. The signiﬁ  cance level was set at 
 Table  1     Demographic and clinical data of patients with systemic lupus 
erythematosus (SLE) and healthy controls  *     
 Characteristics   SLE  (n=250)   Control  (n=122)   p  Value †  
Age (years, (mean±SD)) 42.0±13.1 41.4±13.5 NS
Total cholesterol (mg/dl, 
(mean±SD))
185.1±43.2 183.5±48.0 NS
HDL (mg/dl, (mean±SD)) 56.3±16.8 58.3±15.6 NS
LDL (mg/dl, (mean±SD)) 105.8±34.7 104.8±43.8 NS
Triglycerides 
(mg/dl, (mean±SD))
112.9±70.5 108.4±52.9 NS
High-sensitivity CRP 
(mg/l, (mean±SD))
2.8±6.7 2.0±3.2 NS
History of previous CVD 
(% (n))  ‡ 
8.4 (21) 0 <0.001
Body mass index 26.1±6.5 24.2±5.1 0.002
Family history of CAD 
(% (n))
24.8 (62) 18.0 (22) NS
History of hypertension 
(% (n))  § 
30.8 (77) 16.4 (20) 0.003
History of diabetes (% (n))  ¶  5.2 (13) 0.8 (1) 0.04
History of smoking (current) 
(%  (n)) *  * 
7.6 (19) 12.3 (15) NS
Mean intima-media 
thickness (mm  2 , 
(mean±SD))
0.55±0.14 0.54±0.13 NS
Presence of carotid plaque 
(yes, no) (% (n))
17.2 (43) 13.1 (16) NS
Ethnicity (% (n))
  Caucasian 49.2 (123) 59.8 (73)  
  Asian or Paciﬁ  c Islander 13.2 (33) 21.3 (26)  
  African American 12.8 (32) 9.0 (11)  
  Hispanic 18.4 (46) 8.2 (10)  
  Mixed or other 6.4 (16) 1.6 (2)  
Leptin (ng/ml, (mean±SD)) 23.7±28.0 13.3±12.9 <0.001
Adiponectin 
(µg/ml, (mean±SD))
15.3±8.4 14.0±7.8 NS
Disease duration 
(years, (mean±SD))
11.9±8.5 NA  
SELENA-SLEDAI 
(mean±SD)
3.9±4.0 NA  
SDI damage (mean±SD) 1.3±1.7 NA  
      *    Plus or minus values are mean plus or minus SD.   
  †    p Values shown only if statistically signiﬁ  cant.   
  ‡    Previously documented CVD is deﬁ  ned a history of myocardial infarction, or CAD 
documented on angiogram or stress test, or a previous cerebrovascular event, 
including transient ischaemic attacks (conﬁ  rmed by a doctor) and stroke (conﬁ  rmed by 
appropriate imaging).   
  §    Hypertension was deﬁ  ned as use of antihypertensive drugs or a systolic blood 
pressure >140 mm Hg or a diastolic blood pressure >90 mm Hg.   
  ¶    Diabetes mellitus was deﬁ  ned as the presence of a fasting glucose ≥7.0 mmol/l 
(126 mg/dl), or in subjects receiving insulin or an oral hypoglycaemic agent.   
    *      *  Smoking was present if subjects had smoked any cigarettes within the past 
3 months.   
    CAD, coronary artery disease; CRP, C-reactive protein; CVD, cardiovascular disease; 
HDL, high-density lipoprotein; LDL, low-density lipoprotein; SDI, Systemic Lupus 
International Collaborating Clinics/American College of Rheumatology Damage Index; 
SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; SELENA, Safety of 
Estrogens in Lupus Erythematosus—National Assessment.     
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p<0.05. Multiple regression was used to build models  identifying 
risk factors associated with the presence of plaque and highest 
quartile of leptin levels in patients with SLE.     
  RESULTS 
    Characteristics of the study groups at baseline 
  The SLE and control groups were similar in all demographic 
variables and risk factors except signiﬁ  cantly higher BMI, preva-
lence of hypertension, diabetes and frequency of cardiovascular 
events in the SLE group (  table 1  ).   
    Association of leptin and adiponectin with SLE 
  Patients with SLE had signiﬁ  cantly higher plasma leptin levels 
than controls (p<0.001) (  table 1  ). Because of the known asso-
ciation between high leptin and BMI, subjects were categor-
ised as normal weight (BMI≤24.9) or overweight (BMI≥25.0). 
Both normal weight (p<0.001) and overweight patients with 
SLE (p<0.001) had signiﬁ  cantly higher plasma leptin levels than 
controls (  ﬁ  gure 1  ). Because the overall mean BMI was higher in 
the SLE group than in the controls, we also performed random 
matching of SLE and controls in a 2:1 ratio based on BMI. After 
matching, normal weight (p=0.001) and overweight SLE (p=0.01) 
subjects still had signiﬁ  cantly higher plasma leptin   levels than 
matched controls (online supplementary table 1).     
We also examined the relationships between traditional car-
diac risk factors, disease activity factors and high leptin using 
a bivariate model. Patients with SLE with high leptin, deﬁ  ned 
as the highest quartile of leptin levels (≥29.5 ng/ml), were sig-
niﬁ  cantly more likely to have a higher BMI (p=0.001), previous 
documented CVD (p=0.04) and a higher SDI (p=0.04) (  table 2  ).   
However, when the SDI was separated into components, there 
were no signiﬁ  cant associations between leptin and any indi-
vidual component or organ system. 
  We next performed logistic regression to examine the rela-
tionship between SLE and leptin levels, controlling for potential 
confounders such as traditional cardiac and other risk factors 
signiﬁ   cantly associated with leptin in our study or in other 
published studies. After controlling for traditional risk factors, 
including BMI, the OR for having high leptin levels was 2.7 in 
patients with SLE compared with controls (  table 3  ).   
  Mean plasma adiponectin levels were not signiﬁ  cantly different 
between patients with SLE and controls in our cohort. Because 
low adiponectin levels have been associated with cardiovascular 
risk, we also examined the relationships between low adiponec-
tin, traditional cardiac risk factors and disease activity factors in 
patients with SLE. Those in the lowest adiponectin quartile had a 
higher BMI (p=0.003). No other   signiﬁ  cant associations between 
adiponectin levels and cardiac or disease   factors were found.     
 Figure  1        Mean leptin levels are higher in patients with systemic 
lupus erythematosus (SLE) than in controls, in both normal weight and 
overweight subjects. Each dot represents leptin levels in individual 
patients, stratiﬁ  ed by control vs SLE and normal weight vs overweight 
or obese. The heavy horizontal black lines in each column indicate mean 
scores. Mean leptin levels in each group were then compared using 
analysis of variance with Dunnet’s analysis of comparisons between 
individual  columns    
 Table  2        Disease characteristics of patients with systemic lupus 
erythematosus (SLE) in highest quartile leptin levels compared with 
lowest three quartiles     
 Characteristics 
 Highest 
quartile leptin 
(≥29.5 ng/ml) 
 Lowest  three 
quartiles leptin 
(<29.5 ng/ml) 
 p  Value   n=61   n=189 
Age (years, (mean±SD)) 44.7±13.4 41.8±12.5 NS
History of hypertension 
(% (n))
31.1 (19) 30.7 (58) NS
History of diabetes (% (n)) 4.9 (3) 5.3 (10) NS
History of smoking 
(current) (% (n))
6.6 (4) 7.9 (15) NS
History of previous 
cardiovascular 
disease (% (n))
14.8 (9) 6.3 (12) 0.04
Body mass index 28.5±7.1 25.5±6.1 0.001
Family history of CAD (% (n)) 19.7 (12) 26.5 (50) NS
Previous history of 
glomerulonephritis (%(n))
18.0 (11) 28.0 (53) NS
Total cholesterol 
(mg/dl, (mean±SD))
196.0±48.5 184.4±42.1 NS
HDL (mg/dl, (mean±SD)) 58.0±17.8 56.4±16.7 NS
LDL (mg/dl, (mean±SD)) 115.4±39.0 105.3±34.1 0.08
Triglycerides 
(mg/dl, (mean±SD))
113.3±68.4 110.2±67.7 NS
History of dyslipidaemia 19.7 (12) 15.3 (29) NS
Disease duration 
(years, (mean±SD))
12.9±9.2 12.2±8.0 NS
SELENA-SLEDAI (mean±SD) 3.8±3.4 4.0±4.1 NS
SDI damage (mean±SD) 1.48±1.5 1.2±1.6 0.04
Intima-media thickness 
(mm  2 ,  (mean±SD))
0.57±0.14 0.54±0.14 NS
Presence of carotid plaque 
(yes, no) (% (n))
29.5 (18) 13.2 (25) <0.003
Number of plaques 
(mean±SD)
0.61±1.2 0.30±0.95 0.004
High sensitivity CRP 
(mean±SD)
4.04±11.1 2.4±4.8 NS
Non-Caucasian 
ethnicity (% (n))
26.2 (16) 22.8 (43) NS
Current medication (% (n))
  Mycophenolate mofetil 19.7 (12) 23.3 (44) NS
  Hydroxychloroquine 59.0 (36) 62.4 (118) NS
  Cyclophosphamide 3.3 (2) 0.5 (1) NS
  Azathioprine 6.6 (4) 13.8 (26) NS
Current prednisone 
(mg, (mean±SD))
4.8±9.1 4.3±7.7 NS
6-Month prednisone 
(mg, (mean±SD))
687.0±1041.1 821.7±1304.8 NS
Lp(a) (mg/dl) 24.9±25.9 16.9±9.7 0.01
OxPL/apoB100 (RLU ) 22 035.1±24 583.3 13 895.1±18 182.1 0.02
Proinﬂ  ammatory HDL (% (n)) 60.7 (37) 49.2 (93) <0.001
      CAD, coronary artery disease; CRP, C-reactive protein; HDL, high-density lipoprotein; 
LDL, low-density lipoprotein; OxPL/apoB100, oxidised phospholipids on apoB100; 
SDI, Systemic Lupus International Collaborating Clinics/American College of 
Rheumatology Damage Index; SELENA, Safety of Estrogens in Lupus Erythematosus—
National Assessment; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; 
RLU, relative light units     
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    Correlation between high leptin and proinﬂ  ammatory lipids 
  The relationships between leptin/adiponectin and proinﬂ  amma-
tory lipids such as pro-piHDL, PON1, apoA-1, OxPL/apoB100 
and Lp(a) were examined. Mean leptin levels were signiﬁ  cantly 
higher in patients with SLE and with piHDL than in those with-
out piHDL (26.5±31.8 vs 16.1±17.1, p<0.001), but not in con-
trols (p=0.18). In addition, 60.1% of patients with SLE with high 
leptin levels had piHDL, compared with 49.2% of subjects with 
lower leptin levels (p<0.001). There was also a positive correla-
tion between linear HDL function and leptin (r=0.20, p<0.001). 
Because we have previously shown that piHDL is associated 
with non-Caucasian ethnicity and lifetime prednisone use 
>20 g, we examined whether the association between piHDL 
and leptin was mediated by the presence of these and other pos-
sible confounders, including tobacco use, age, BMI and hyper-
tension. Using logistic regression, we found that the relationship 
between piHDL and leptin was still signiﬁ  cant (p=0.02) (online 
supplementary table 2). There were no signiﬁ  cant relationships 
between levels of apoA-I or PON1 activity (both protective 
components of HDL). In addition, there was no signiﬁ  cant rela-
tionship between adiponectin and HDL function. 
  Lp(a) levels were also signiﬁ   cantly correlated with leptin 
  values (r=0.19, p=0.01), and were higher in subjects in the high-
est quartile of leptin levels than in those in the lowest three 
quartiles (p=0.01). OxPL/apoB100 levels were also higher in 
patients with SLE with high leptin than in those with low leptin 
levels (p=0.02) (  table 2  ). OxPL/apoB100 levels were also signiﬁ  -
cantly correlated with continuous leptin levels (r=0.17, p=0.02) 
(online supplementary ﬁ  gure 1).   
    Leptin levels are associated with the presence of subclinical 
atherosclerosis in patients with SLE, even after accounting 
for traditional cardiac and disease factors 
  Among the 250 patients with SLE in this cohort, mean leptin 
levels were higher in the 43 patients with plaque than in those 
without plaque (p=0.002) and were also signiﬁ  cantly higher in 
control subjects with plaque (p<0.001) (  ﬁ  gure 2  ). Bivariate analy-
sis showed that 41.9% of patients with SLE with plaque had 
high leptin, compared with 20.8% of patients with SLE with-
out plaque (p=0.003) (online supplementary ﬁ  gure 2). The mean 
number of carotid plaques was also higher in both patients with 
SLE (p=0.004) (  table 2  ) and controls (p=0.004) with high lep-
tin levels. Mean leptin levels were also weakly correlated with 
carotid IMT in patients with SLE (r=0.14, p=0.03). There were 
no associations between leptin levels and plaque location or 
characteristics in either SLE or control subjects.     
Multivariate analysis was used to examine the association of 
leptin and carotid plaque in patients with SLE after accounting for 
potential confounders, including traditional cardiac risk factors 
and SLE associated factors. After analysis, the signiﬁ  cant factors 
associated with carotid plaque were high leptin levels, piHDL, 
age, hypertension and current tobacco use (  table 4  ). The associa-
tion between high leptin and IMT was no longer signiﬁ  cant after 
controlling for traditional cardiac and SLE disease factors.     
    Association of adiponectin with plaque in patients with SLE 
  Among the 250 patients with SLE in this cohort, mean adi-
ponectin levels were non-signiﬁ  cantly higher in patients with 
SLE with versus without plaque (17.0±12.3 vs 14.6±7.5, p=0.1). 
There was no signiﬁ  cant correlation between adiponectin and 
carotid IMT in patients with SLE.     
  DISCUSSION 
  SLE is associated with an increased risk of subclinical and 
clinical atherosclerosis,  1    –    3   although the biological mechanisms 
underlying this risk are not well understood. Data presented 
here describe high levels of plasma leptin in women with SLE, 
and an association between high leptin and carotid plaque in 
bivariate and multivariate analysis. To our knowledge, this is 
the ﬁ  rst study to report a signiﬁ  cant association between leptin 
and subclinical atherosclerosis in SLE. Chung   et al    23   found no 
signiﬁ  cant relationship between leptin or adiponectin levels and 
coronary calciﬁ  cation in 109 patients with SLE and 78 control 
subjects. Possibly, the larger sample size in our study allowed 
 Figure  2     Mean leptin levels are higher in patients with systemic 
lupus erythematosus (SLE) and control subjects with plaque than in 
those without plaque. Each dot represents leptin levels in individual 
patients, stratiﬁ  ed by control vs SLE and plaque vs no plaque. The heavy 
horizontal black lines in each column indicate mean scores.       
 Table  4        Logistic regression of the relationship of systemic lupus 
erythematosus with the presence of plaque on carotid ultrasound   
 Explanatory  variable   OR   95%  CI   p  Value 
Highest quartile leptin (yes, no) 2.8 1.07 to 7.4 0.03
Pro-inﬂ  ammatory high-density 
lipoprotein (yes, no)
12.8 3.5 to 47.1 <0.001
Age (years) 1.1 1.07 to 1.2 <0.001
Hypertension (yes, no) 3.0 1.1 to 7.7 0.01
Current smoking (yes, no) 7.7 1.4. to 44.0 0.03
History of dyslipidaemia (yes, no) 3.7 0.98 to 9.0 0.06
Diabetes (yes, no) 2.0 0.2 to 17.2 NS
Body mass index (kg/m  2  ) 1.01 0.94 to 1.1 NS
Previous documented cardiovascular 
disease (yes, no)
0.54 0.2 to 2.6 NS
Non-Caucasian ethnicity 1.9 0.7 to 4.9 NS
Lifetime prednisone >20 g (yes, no) 2.4 0.7 to 8.0 NS
Disease duration 1.05 0.98 to 1.1 NS
SDI 0.8 0.5 to 1. 2 NS
          hsCRP,  high  sensitivity  C-reactive  protein;  SDI,  Systemic  Lupus  International 
Collaborating Clinics/American College of Rheumatology Damage Index.     
 Table  3        Logistic regression of the relationship of systemic lupus 
erythematosus (SLE) with the highest quartile of leptin levels   
 Explanatory  variable   OR   95%  CI   p  Value 
SLE diagnosis (yes, no) 2.7 1.3 to 5.9 0.01
Age (years) 1.0 0.98 to 1.03 NS
History of dyslipidaemia (yes, no) 1.3 0.6 to 2.7 NS
Hypertension (yes, no) 0.7 0.4 to 1.3 NS
Current smoking (yes, no) 0.96 0.3 to 2.7 NS
Diabetes (yes, no) 0.8 0.2 to 3.1 NS
High sensitivity C reactive protein (mg/l) 1.02 0.98 to 1.06 NS
Body mass index (kg/m  2  ) 1.05 1.01 to 1.1 0.02
Any cardiovascular disease history (yes, no) 2.7 0.98 to 7.3 0.06
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us to see signiﬁ  cant associations in SLE. Alternatively, it is pos-
sible that leptin is associated with plaque in lupus but not with 
coronary calciﬁ  cation. 
  In one recently published meta-analysis, the authors con-
cluded that the moderate association between leptin and car-
diovascular events in the general population is largely based 
on BMI.  24   In our study, although leptin levels correlated with 
BMI in patients with SLE, multiple analyses controlling for BMI 
conﬁ  rmed an independent association between high leptin and 
carotid plaque. Thus, in our cohort, the inﬂ  uence of leptin on 
risk of atherosclerosis in SLE appears to be at least partly inde-
pendent of its association with obesity. 
  Interestingly, we saw an association between high leptin 
levels and the proinﬂ  ammatory lipids piHDL, Lp(a) and OxPL/
apoB100. At least 45% of patients with SLE have piHDL, 
and piHDL confers a 16-fold increased risk of the presence of 
plaque.  14     25   In this cohort, piHDL was associated with high lep-
tin levels after accounting for the presence of plaque, suggest-
ing an independent association between piHDL and leptin.  26   
Recent animal data from our group supports the idea that leptin 
may directly promote piHDL formation in an SLE-prone mouse 
model (BWF1).  27   The mechanisms that lead to this association, 
however, are still unclear. 
  Several authors have suggested that increased oxidative stress 
may be responsible for the formation of piHDL and other oxidised 
lipids.  28     29   Increased leptin levels are known to induce oxidative 
stress by increasing the accumulation of reactive oxygen species, 
and serum leptin levels have previously been correlated with oxi-
dised low-density lipoprotein in postmenopausal women.  30   In 
our cohort, we also found a correlation between the inﬂ  amma-
tory lipids Lp(a), OxPL/apoB100 and leptin. Lp(a) is a risk factor 
for CVD in the general population, and it has been suggested that 
at least one mechanism by which this occurs is via its content 
of proinﬂ  ammatory OxPL.  22     31   We have previously shown that 
nearly all of the OxPL associated with lipoproteins in plasma is 
associated with Lp(a) and have proposed that Lp(a) acts as   carrier 
of such OxPL. Therefore, OxPL/apoB100 probably reﬂ  ects the 
biological capacity of Lp(a) to bind and transport OxPL. Previous 
studies in SLE have demonstrated an association between OxPL/
apoB100 and CVD  32     33   and renal disease.  33   In our cohort, the cor-
relation of OxPL/apoB100 and Lp(a) in patients with SLE was very 
high (r=0.96, p<0.0001), much higher than previously reported 
in patients with non-rheumatic disease (r=0.68, p<0.0001).  22   
Possibly, this suggests that there is an ongoing enhanced state 
of oxidative stress in patients with SLE, which is reﬂ  ected in the 
increased content of OxPL/apoB and Lp(a) and their high corre-
lation with each other. Taken together, these data suggest that 
leptin contributes to increased oxidation, but further studies are 
required to determine whether hyperleptinaemia in patients with 
SLE contributes directly to increased oxidative stress. 
  There are several other mechanisms by which leptin might 
directly promote atherosclerosis. Leptin has been shown to 
increase accumulation of cholesterol esters in foam cells, espe-
cially in hyperglycaemic conditions.  34   It also activates circulating 
monocytes, induces monocyte proliferation  35   and upregulates 
endothelial cell production of monocyte chemoattractant pro-
tein 1.  26   In vitro, leptin treatment stimulates monocyte produc-
tion of tumour necrosis factor α and interleukin 6.  36   
  In addition, leptin levels are inversely associated with physical 
activity in the general population.  37     38   We previously described a 
inverse association between physical activity and carotid plaque 
and increased IMT in subjects with SLE.  39   Indeed, in this SLE 
cohort, we found that leptin levels were signiﬁ  cantly  lower 
in subjects with high total weekly exercise levels (deﬁ  ned as 
≥225 mets/week) (p<0.001). However, even when exercise lev-
els were entered into our multivariate analyses, the signiﬁ  cant 
associations between high leptin, piHDL and plaque in SLE still 
remained constant (data not shown). 
  Although low levels of adiponectin have been associated 
with atherosclerosis,  40   our study and several previous studies 
found that plasma adiponectin levels are similar or raised in 
patients with SLE compared with controls.  11     41   A recent study 
by Reynolds   et al  ,  42   also found an association between high adi-
ponectin levels and carotid plaque in SLE; however, we did not 
ﬁ  nd a signiﬁ  cant association between adiponectin and plaque 
in our cohort. It is possible that the exclusion of men and/or 
the higher proportion of Caucasian subjects in our study may 
account for this difference. 
  Our study has some limitations. The prevalence of plaque in 
our group was lower than in previously published cohorts,  2     43   
and was not signiﬁ  cantly different between SLE and control sub-
jects. Possible explanations include our exclusion of individuals 
taking statins (thus excluding many with known hyperlipidae-
mia and/or clinical atherosclerosis  17  ) and inclusion of a higher 
proportion of Asians, who may have a lower prevalence of 
atherosclerosis than other racial groups.  44   Similarly, we did not 
see any signiﬁ  cant difference between mean carotid IMT in SLE 
and control subjects. This mirrors ﬁ  ndings in two other large US 
SLE cohort studies in which cross-sectional IMT  2   and IMT pro-
gression  45   did not differ between SLE and controls. In contrast, 
several smaller European and US studies do demonstrate higher 
IMT in SLE.  42     46    –    48     Again, this discrepancy in our cohort might 
be due to the exclusion of statins. Also, the frequency of smok-
ing in the European studies was much higher than in our group, 
raising the possibility that tobacco use might play a synergistic 
role in acceleration of atherosclerosis in SLE. 
  Finally, our study examines associations between leptin and 
subclinical atherosclerosis rather than cardiovascular events. 
Although carotid plaque and IMT are known to be associated 
with cardiovascular events in the general population,  49   this asso-
ciation has not been fully established in SLE. Notably, however, 
although the overall incidence of cardiac events was low in our 
cohort, previously documented CVD was signiﬁ  cantly  more 
common in patients with SLE with carotid plaque (16.3%) than 
in those without (6.8%) (p=0.04). 
  In summary, this study shows that high leptin levels contribute 
to a 2.8-fold increased odds for the presence of atherosclerosis 
in female patients with SLE. Future prospective and mechanistic 
studies are needed to establish leptin as a causative factor for 
plaque formation in SLE. 
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